TRDA · CIK 0001689375
Entrada Therapeutics, Inc.
What Entrada Therapeutics, Inc. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
Entrada Therapeutics, Inc. - Profile
- Industry
- Pharmaceutical PreparationsSIC 2834
- Listed on
- Nasdaq
- Employees
- 152stated 2026
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Entrada Therapeutics, Inc.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2026. The description was written for this site in August 2026 from Entrada Therapeutics, Inc. Form 10-K for fiscal year 2025 and Entrada Therapeutics, Inc. Form 10-Q for the quarter ended 30 June 2026, not taken from any single article.
Share price
TRDA
Description
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company in Boston developing intracellular therapeutics on its Endosomal Escape Vehicle (EEV) platform. An EEV is a cyclic peptide that binds the cell's phospholipid bilayer, triggers endocytosis, then escapes the endosome so a conjugated oligonucleotide or protein reaches the cytosol. Its lead franchise is four EEV-PMO exon-skipping conjugates for Duchenne muscular dystrophy, led by ENTR-601-44. That candidate's IND was on clinical hold until Entrada resolved it in February 2025. In the second quarter 2026 report, Cohort 2 of the Phase 1/2 ELEVATE-44-201 trial was fully enrolled with topline data due in the first quarter of 2027, and ELEVATE-45-201 Cohort 1 data due in October 2026. Under a collaboration and license agreement with Vertex Pharmaceuticals, Vertex holds an exclusive worldwide license to VX-670 for myotonic dystrophy type 1; Entrada received $223.7 million upfront plus a $26.3 million equity investment and is eligible for up to $485.0 million in milestones. Collaboration revenue was $25.4 million in 2025 against a $143.8 million net loss, and $1.8 million in the first half of 2026 against an $82.5 million loss. Cash and marketable securities were $223.0 million at 30 June 2026, expected to fund operations into the third quarter of 2027. Entrada had 152 full-time employees as of 19 February 2026.
Who owns Entrada Therapeutics, Inc..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 116 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
116 managers reported a position, together holding 25.5m shares, or 65.6% of the company. The 40 largest are listed. Percentages are of the 38.8m shares outstanding at 30 Apr 2026, the count in force when this quarter was measured rather than the count today.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 29384C108, held by ameriprise, bank-of-america, blackrock, bny-mellon, citigroup, fidelity-fmr, geode, goldman-sachs, invesco, jpmorgan, merck, metlife, morgan-stanley, northern-trust, pnc, state-street, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.